Oncothermia Journal Volume 11

The list of the cases Local Type Number of cases Bone Bone metastases

“Purpose: Deep heating electro-hypertermia methods are a promising cancer treatment modalities used to enhance conventional treatment. This could be achieved through radiofrequency field on 8 and 13.56 MHz by Thermotron RF-8 and Oncotherm-Labehy, respectively. However, the difference cytotoxic effect between different hyperthermia devices has never been evaluated. ….”

“Introduction: Cancer has limited curative possibilities in high-line treatments. Our objective study modulated electro-hyperthermia (mEHT) [2], as monotherapy, treating patients in advanced stages, when other possibilities was not applicable. ….”

“Introduction: After surgery sarcoma has high incidence of local recurrence and distant metastases. It is mostly resistant on radiotherapy and shows only limited response to chemotherapy. Presently a study showed the efficacy of conventional hyperthermia for sarcoma cases [1]. Our objective study modulated electro-hyperthermia (mEHT) [2], combined with conventional therapies for various sarcomas. …”

“Background: Previously, we investigated whether radiotherapy can elicit immunoreaction which, we think, is mediated by abscopal effect. On the other hand, modulated electro-hyperthermia (mEHT) was developed and it is still unknown whether mEHT can elicit immunoreaction or not. Therefore, we conducted a basic and clinical research. …”

“Electromagnetic therapy in terms of biological effect is initially 'a unity of opposites', namely of the specific, non-thermal effect of alternating electromagnetic fields and inevitable nonspecific heating, each having its own efficiency. First, 'the struggle of the opposites' led to negation of any role of non-thermal effects and absolutisation of the thermal component, resulted in the formation of so-called 'thermal dogma' in 30s. Temperature oncological hyperthermia based on the 'thermal dogma' failed in terms of implementation after 50 years of development.

“Introduction: Management of patients suffering from esophageal cancer with lung metastasis remains challenging in routine clinical practice. Oncothermia has recently been applied as novel therapeutic option for metastatic or recurrent esophageal cancer patients. We report a case of esophageal cancer patient with showing a restricted response in the Oncothermia application field during TS-1 systemic chemotherapy. …”

“Purpose: In the present study, we investigated the potential of oncothermia (electro·hyperthermia) for an alternative therapeutic option of pan-human cancer. Materials and methods: To address this issue, we applied oncothermic heating (42 centigrade 1 hour, three times with a two- or three-day interval) to various human cancer cell lines such as A549 Oung cancer), HepG2 Oiver cancer), MDA-MB231 (breast cancer) and A172 & U-87MG (brain cancer), and then examined for cancer cell phenotypic changes.

  “Background: Oncothermia clinical applications have been started in the 1990s in Germany. It is a German medical method based on a Hungarian invention which reached the approval in the European Union in 1998, and is still rapidly spreading all over the world. Oncothermia is nowadays present in 30+ countries, and 100,000+ treatments are provided per year. Together with the 'classical' EHY2000 locoregional device, the intraluminal EHY1000 and the multilocal EHY3000 series are popular on the market.

“Background: Oncothermia has a quarter-century history [1]. It was started by typical invasive solution (ECT, electro-cancer-therapy) and tried also invasive interstitial technology; even systemic heating was also in the production range. However, the non-invasive loco-regional (EHY2000 series) and the multilocal (EHY3000 series) products, together with the intraluminar application (EHY1000 series) became popular among professionals. Why has Oncotherm tried so many forms of synergy of electric and thermal effects?

“Introduction: Oncothermia method (OTM) is a long time applied tumor treatment modality in the human clinical practice. Experimental results showed that OTM can effectively and selectively destroy the tumor tissue, but recent investigations revealed some unusual immunological aspect of OTM. The immunogenic characteristics of immunogenic cell death (ICD) are mainly mediated by damage-associated molecular patterns (DAMPs). We summarize our results regarding the OTM induced ICD in Study I.

“Purpose: Oncothermia is a significant and definite technical development in the hyperthermia field, using capacitive (impedance) coupling of 13.56MHz amplitude-modulated radiofrequency energy on the tumor site. As a result, turning local apoptosis effect into a systemic anti-tumor immune response is possible. Oncothermia method is capable of turning tumor microenvironment into an immunological more favorable environment. In this study, our aim was to enhance the therapeutic effect of dendritic cells (DCs) immunotherapy after Oncothermia treatment. …”

“Background: Hyperthermia could not find its established place among the 'gold standards' of the oncotherapies until now. We have to understand better the basic effects induced thermally and/or non-thermally. Challenges: Dosing of hyperthermia is completely different from other therapies. In case of hyperthermia the dose connected to tumortemperature which is indefinite, spread by blood and surrounding tissues. There are numerous electromagnetic hyperthermia methods distinguished by the kind of the fields, frequencies, heated volume, and conjunction with other methods, etc.

“Nowadays, most oncologists face the challenge of ideal therapies without side-effects for cancer treatment. Conventional Hyperthermia can not achieve curative higher temperature in deep-seated tumors. Oncothermia can raise temperature and changing pH environment around the tumor. Combination of oncothermia with chemotherapy may enhance chemo-sensitivity, induce higher drug concentration around and inside the tumor, resulting tumor destruction.

“Modulated electro-hyperthermia is an emerging complementary treatment option for refractory solid tumor. Early experience suggests that it may have advantages over conventional hyperthermia with exceeding efficacy, and less complication. Herein, we describe a case of chemo-resistant, recurrent endometrial cancer patient; a successful conversion of chemo-sensitivity by the combination of electro-hyperthermia. On the way of chemotherapy for relapsed endometrial cancer, elevation of CA-125 marker frequently means chemo-resistance of the tumor.